![iscribe co in iscribe co in](https://essentialpicks.com/wp-content/uploads/unboxing-iScribe-notepad-768x612.jpg)
and has been its Director since January 2003.
![iscribe co in iscribe co in](https://media.glassdoor.com/sqll/597572/spider-software-squarelogo-1399054890400.png)
He served as a Co-Chairman of the UCSF Capital Campaign. He served as the Chairman of Biogen Idec Inc., Idec Pharmaceuticals, Ligand Pharmaceuticals, Hybritech, Athena Neurosciences and That Man May See (UCSF) Vision Research Foundation. He serves as the Chairman of OptiMedica Corporation. He served as the President and Director of the Western Association of Venture Capitalists. Byers has been a venture capital investor since 1972 and has been closely involved with more than 50 new technology based companies over half of which have already become public companies. He served as the founding President and then the Chairman of four biotechnology companies incubated in its office. Byers formed the first venture capital Life Science Practice Group in 1984, helping it to become a premier venture capital firm in the medical, healthcare, and biotechnology fields. Byers is a part of pandemic and biodefense and life sciences team. and KPCB Information Sciences Zaibatsu Fund II, L.P. Byers, Ph.D., is a Partner at KPCB Digital Growth Fund, L.P., Kleiner Perkins Caufield & Byers XI, L.P., Kleiner Perkins Caufield & Byers XII, L.P., Kleiner Perkins Caufield & Byers XIII, L.P.